Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%–30% of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Falvella, Felicia Stefania, Caporale, Marta, Cheli, Stefania, Martinetti, Antonia, Berenato, Rosa, Maggi, Claudia, Niger, Monica, Ricchini, Francesca, Bossi, Ilaria, Di Bartolomeo, Maria, Sottotetti, Elisa, Bernardi, Francesca Futura, de Braud, Filippo, Clementi, Emilio, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425114/
https://www.ncbi.nlm.nih.gov/pubmed/25906475
http://dx.doi.org/10.3390/ijms16048884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425114/
https://www.ncbi.nlm.nih.gov/pubmed/25906475
http://dx.doi.org/10.3390/ijms16048884

Ejemplares similares